In August, OCRA hosted a listening session with the U.S. Food and Drug Administration (FDA) to better understand the impact of Covid-19 on clinical trial participation.
Watch the full FDA listening session in the video below.
Related Topics
The Overview: October 2026
OCRA’s Rivkin Ovarian Cancer Research Symposium Convenes A Scientific Community Ready To Accelerate Progress More than 375 researchers, clinicians, and advocates gathered in Philadelphia for the 16th Biennial Rivkin Ovarian Cancer Research Symposium, presented for the first time by Ovarian Cancer Research Alliance (OCRA). Founded in 1996, the Symposium is the longest-standing meeting dedicated to … Continued
OCRA’s Advocate’s Corner: October 2026
Written by Julia Thayer, OCRA’s Associate Director, Advocacy September was an especially busy month at Ovarian Cancer Research Alliance (OCRA), filled with awareness activities, OCRA’s International Gynecologic Cancer Conference®, and more. But our work continues year-round. 2027 Advocate Leaders Program Draws More Than 100 New Applicants Preparations are already underway for the 2027 Advocate Leaders Program, … Continued
OCRA Sponsors NCCN Guidelines for Cervical, Ovarian, and Uterine Cancer Patients
This article was updated in October 2026 to reflect NCCN’s release of the 2026 Guidelines for Ovarian Cancer Patients. OCRA is a proud sponsor of the 2026 Patient Guidelines for Ovarian Cancer, Cervical Cancer, and Uterine Cancer. We believe ensuring access to clear, understandable information is critical. NCCN provides wonderful guides for anyone newly diagnosed … Continued